Michael D Levin

US Patent:

7700329, Apr 20, 2010

Filed:

Oct 20, 2004

Appl. No.:

10/576122

Inventors:

Brian Morgan - San Diego CA, US
Mark Burk - San Diego CA, US
Michael Levin - San Diego CA, US
Zuolin Zhu - San Diego CA, US
Jennifer Chaplin - San Diego CA, US
Karen Kustedjo - San Diego CA, US
Zilin Huang - Bellevue WA, US
William Greenberg - San Diego CA, US

International Classification:

C12P 17/06
C12P 17/12
C12P 17/18

US Classification:

435125, 435123, 435158

Abstract:

The invention provides synthetic chemical and chemoenzymatic methods of producing simvastatin and various intermediates. In one aspect, enzymes such as hydrolases, e. g. , esterases, are used in the methods of the invention.

US Patent:

20030044864, Mar 6, 2003

Filed:

Jul 22, 2002

Appl. No.:

10/202399

Inventors:

Jay Short - Rancho Santa Fe CA, US
Martin Latterich - San Diego CA, US
Jing Wei - San Diego CA, US
Michael Levin - San Diego CA, US

Assignee:

Diversa Corporation - San Diego CA

International Classification:

G01N033/574
G06F019/00
G01N033/48
G01N033/50

US Classification:

435/007230, 702/019000

Abstract:

The invention provides cellular transformation, directed evolution, and screening methods for creating novel transgenic organisms having desirable properties. Thus in one aspect, this invention relates to a method of generating a transgenic organism, such as a microbe or a plant, having a plurality of traits that are differentially activatable. Also, a method of retooling genes and gene pathways by the introduction of regulatory sequences, such as promoters, that are operable in an intended host, thus conferring operability to a novel gene pathway when it is introduced into an intended host. For example a novel man-made gene pathway, generated based on microbially-derived progenitor templates, that is operable in a plant cell. Furthermore, a method of generating novel host organisms having increased expression of desirable traits, recombinant genes, and gene products. Additionally, the invention provides novel methods for determining polypeptide profiles, and protein expression variations, which methods are applicable to all sample types disclosed herein. The present invention provides methods of simultaneously identifying and quantifying individual proteins in complex protein mixtures. Protein expression levels can be globally quantified.

US Patent:

20050124010, Jun 9, 2005

Filed:

Oct 1, 2001

Appl. No.:

10/398271

Inventors:

Jay Short - Rancho Santa Fe CA, US
Pengcheng Fu - Lowrey Avenue HI, US
Jing Wei - San Diego CA, US
Michael Levin - San Diego CA, US
Martin Latterich - Montellano Terrace, San Diego CA, US

International Classification:

G01N033/574
G06F019/00
G01N033/48
G01N033/50

US Classification:

435007230, 702019000

Abstract:

This invention relates to the field of cellular and whole organism engineering. Specifically, this invention relates to a cellular transformation, directed evolution, and screening method for creating novel transgenic organisms having desirable properties. Thus in one aspect, this invention relates to a method of generating a transgenic organism, such as a microbe or a plant, having a plurality of traits that are diffenentially activatable.

US Patent:

20050202426, Sep 15, 2005

Filed:

Oct 1, 2002

Appl. No.:

10/491358

Inventors:

Jay Short - Rancho Sante Fe CA, US
Martin Latterich - Montreal, CA
Michael Levin - San Diego CA, US
Jing Wei - San Diego CA, US
Pengcheng Fu - Honolulu HI, US

International Classification:

C12Q001/68
C12N015/85

US Classification:

435006000, 435455000

Abstract:

The invention provides methods for whole cell engineering of new and modified phenotypes by using “on-line” or “real-time” metabolic flux analysis. The invention provides a method for whole cell engineering of new or modified phenotypes by using real-time metabolic flux analysis by making a modified cell by modifying the genetic composition of a cell and culturing the modified cell to generate a plurality of modified cells and measuring at least one metabolic parameter of the cell by monitoring the cell culture of in real time. The invention also provides articles comprising machine-readable medium including machine-executable instructions and systems, e.g., computer systems, to practice the methods of the invention.

US Patent:

20110059493, Mar 10, 2011

Filed:

Apr 19, 2010

Appl. No.:

12/763198

Inventors:

Brian Morgan - San Diego CA, US
Mark Burk - San Diego CA, US
Michael Levin - San Diego CA, US
Zuolin Zhu - Huaibie, CN
Jennifer Chaplin - San Diego CA, US
Karen Kustedjo - San Diego CA, US
Zilin Huang - San Leandro CA, US
William Greenberg - San Diego CA, US

International Classification:

C12P 17/06
C12N 9/14
C12P 7/42

US Classification:

435125, 435195, 435146

Abstract:

The invention provides synthetic chemical and chemoenzymatic methods of producing simvastatin and various intermediates. In one aspect, enzymes such as hydrolases, e.g., esterases, are used in the methods of the invention.

US Patent:

20200171165, Jun 4, 2020

Filed:

Nov 29, 2019

Appl. No.:

16/699455

Inventors:

- La Jolla CA, US
Philip Sung-Whan OH - San Diego CA, US
Adrian CHRASTINA - Chula Vista CA, US
Michael D. LEVIN - San Diego CA, US
Bogdan Z. OLENYUK - Poway CA, US
Rajesh KOTA - San Diego CA, US

Assignee:

Proteogenomics Research Institute for Systems Medicine - La Jolla CA

International Classification:

A61K 47/68
A61K 31/704
A61K 31/337
A61K 33/243
A61K 51/10
C07K 16/22
C07K 16/32
C07K 16/18
A61K 47/69
A61P 35/00
A61P 35/04

Abstract:

Methods and compositions for enhancing the therapeutic activity of agents at low doses as a result of improved targeted drug delivery, namely precision delivery, are described. The methods and compositions can be used to decrease the effective administered amounts of active therapeutic agents via precision delivery to targets capable of mediating active transport across the biological barrier formed by the vasculature that lines blood vessels. Antibodies (and other targeting agent species) to precisely deliver an active ingredient (i.e., a therapeutic agent) to cells expressing, for example, a target protein on their cell membranes, are also described, as are methods of treating disease.